There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Plus Therapeutics (PSTV – Research Report), Ambrx Biopharma (AMAM – Research Report) and Marinus (MRNS – Research Report) with bullish sentiments.
Plus Therapeutics (PSTV)
H.C. Wainwright analyst Sean Lee CFA maintained a Buy rating on Plus Therapeutics today and set a price target of $8.00. The company’s shares closed last Monday at $1.90, close to its 52-week low of $0.97.
According to TipRanks.com, CFA ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Plus Therapeutics with a $14.67 average price target.
See today’s best-performing stocks on TipRanks >>
Ambrx Biopharma (AMAM)
TD Cowen analyst Phil Nadeau maintained a Buy rating on Ambrx Biopharma today. The company’s shares closed last Monday at $9.69.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ambrx Biopharma with a $25.17 average price target, which is a 155.8% upside from current levels. In a report issued on November 14, RBC Capital also maintained a Buy rating on the stock with a $32.00 price target.
Marinus (MRNS)
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Marinus today and set a price target of $27.00. The company’s shares closed last Monday at $6.13.
According to TipRanks.com, Tsao is a 2-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Marinus with a $18.75 average price target, a 200.5% upside from current levels. In a report issued on November 7, TD Cowen also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PSTV:
- Plus Therapeutics to Host Virtual KOL Event on New Phase 2 ReSPECT-GBM Data in Recurrent Glioblastoma Presented at the Society for NeuroOncology (SNO) Conference on Monday, November 20, 2023
- Plus Therapeutics files to sell 1.3M shares of common stock for holders
- Biotech Alert: Searches spiking for these stocks today
- Plus Therapeutics granted Orphan Drug Designation for rhenium obisbemeda
- Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to Rhenium (186Re) Obisbemeda for the Treatment of Breast Cancer with Leptomeningeal Metastases
